Active, not recruitingPHASE1, PHASE2NCT02690545
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
Studying T-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Principal Investigator
- Anne Beaven, MDDirector, UNC Lineberger Lymphoma Program
- Intervention
- ATLCAR.CD30 cells(biological)
- Enrollment
- 38 enrolled
- Eligibility
- 3 years · All sexes
- Timeline
- 2016 – 2039
Study locations (1)
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02690545 on ClinicalTrials.govOther trials for T-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05989204TmCD19-IL18 in CD19+ CancersUniversity of Pennsylvania
- ACTIVE NOT RECRUITINGPHASE1NCT05377827Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic MalignanciesWashington University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT04440436Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) PatientsBeijing Immunochina Medical Science & Technology Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE1NCT03434769AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin LymphomaBenjamin Tomlinson